Clinical Trial Update: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document reports an update on a Phase 2 trial evaluating telisotuzumab vedotin (ABBV-399) in patients with previously treated c-Met–positive non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Snippet

Sponsor: AbbVie | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING